Reading Time: 7 minutesThis is blog number 13 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Tag: biomarkers
Reading Time: 9 minutesA paper arising from research carried out at the University of Sheffield as part of the AMBRoSIA biobank, and in collaboration with the international Project
Reading Time: 4 minutesThis blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters
Reading Time: 4 minutesRecently published results from the open-label Lighthouse trial investigating safety of the drug Triumeq in people with MND revealed the treatment was safe and ready
Reading Time: 10 minutes“The annals of ALS clinical trials is strewn with failed studies. Only two out of more than 70 clinical trials have been positive, and even
Reading Time: 3 minutesThis blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 7 minutesIn the last decade, the MND Association has invested millions in research within the UK and across the world. We are a leader in the
Reading Time: 8 minutesFollowing on from our previous catch-up blog on clinical management talks presented at the Symposium, here is a continuation that looks at talks focusing on
Reading Time: 3 minutesThe AMBRoSIA (A Multicentre Biomarker Resource Strategy In ALS) project is our biggest, most ambitious research undertaking to date. The project funding began in August,